Tirier C, Zhang Y, Plendl H, Weber-Matthiesen K, Langer W, Heit W, Schlegelberger B
Department of Hematology/Oncology, Evangelic Hospital Essen-Werden, Germany.
Leukemia. 1996 Feb;10(2):346-50.
Little is known about the clinical significance of secondary chromosome aberrations in lymphomas with t(11;14)(q13;q32), the characteristic change of mantle cell lymphomas. Here we present a patient with mantle cell lymphoma, who showed a variant Burkitt's translocation t(2;8)(p12;q24) in addition to t(11;14) during the progression of the disease. An involvement of chromosome 8q24, the localization of the c-myc gene, has so far been described in only four patients, who seemed to have a fatal clinical course. Although no blastic transformation occurred in our patient, no remission could be induce by intensified treatment and survival was only 5 months. This case demonstrates that secondary chromosome aberrations can determine the clinical course of patients, even if morphologic and immunophenotypic findings fail to predict the poor outcome.
关于套细胞淋巴瘤特征性改变t(11;14)(q13;q32)的淋巴瘤中继发性染色体畸变的临床意义，目前所知甚少。在此，我们报告1例套细胞淋巴瘤患者，其在疾病进展过程中除了t(11;14)外，还出现了变异型伯基特淋巴瘤易位t(2;8)(p12;q24)。8号染色体q24区（c-myc基因的定位区域）受累，迄今为止仅在4例患者中被描述过，这些患者似乎都有致命的临床病程。尽管我们的患者未发生母细胞转化，但强化治疗未能诱导缓解，生存期仅5个月。该病例表明，继发性染色体畸变可决定患者的临床病程，即便形态学和免疫表型结果未能预测不良预后。
